Results 21 to 30 of about 5,561 (172)

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging

Haematologica, 2011
Background Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and ...
Alessia Pepe, Antonella Meloni, Marcello Capra, Paolo Cianciulli, Luciano Prossomariti, Cristina Malaventura, Maria Caterina Putti, Alma Lippi, Maria Antonietta Romeo, Maria Grazia Bisconte, Aldo Filosa, Vincenzo Caruso, Antonella Quarta, Lorella Pitrolo, Massimiliano Missere, Massimo Midiri, Giuseppe Rossi, Vincenzo Positano, Massimo Lombardi, Aurelio Maggio   +19 more
doaj   +1 more source

Desensibilización a deferasirox en una paciente con hemocromatosis. Reporte de un caso

Revista Alergia México, 2023
Antecedentes: Deferasirox es un quelante de hierro activo, indicado en el tratamiento de pacientes con hemocromatosis; sin embargo, se ha informado que el 28% de los casos puede tener reacciones adversas al fármaco. El protocolo de desensibilización para
Nadia Karina Aguilar Hinojosa, Evelyn Itzamara Figueroa Saavedra   +1 more
doaj   +1 more source

Acute kidney injury due to thin basement membrane disease mimicking Deferasirox nephrotoxicity: a case report

BMC Nephrology, 2018
Background Although the renal toxicity of Deferasirox, an oral iron chelator, has been reported to be mild, there have been reports of acute interstitial nephritis or Fanconi syndrome due to this agent.
Keiko Oda, Kan Katayama, Akiko Tanoue, Tomohiro Murata, Yumi Hirota, Shoko Mizoguchi, Yosuke Hirabayashi, Takayasu Ito, Eiji Ishikawa, Kaoru Dohi, Masaaki Ito   +10 more
doaj   +1 more source

Advances in iron chelation therapy: transitioning to a new oral formulation

Drugs in Context, 2017
Iron overload is a concern for patients who require repeated red-blood-cell transfusions due to conditions such as sickle cell disease, thalassemia, or myelodysplastic syndromes.
Nirmish R Shah
doaj   +1 more source

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

Experimental Hematology & Oncology, 2020
Background Despite the proven benefits of iron chelation therapy (ICT) in the management of chronic iron overload and related complications, compliance to long-term ICT is challenging.
Immacolata Tartaglione, Raffaella Origa, Antonis Kattamis, Michael Pfeilstöcker, Sibel Gunes, Susanne Crowe, Niamh Fagan, Beatrice Vincenzi, Giovan Battista Ruffo   +8 more
doaj   +1 more source

Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With beta-Thalassemia Major: Once-daily Versus Twice-daily Administration

, 2017
Purpose: Deferasirox (DEFR), when administered BID, improves iron overload and decreases DEFR-related adverse effects in patients with beta-thalassemia major.
Lu, Meng-Yao;Wang, Ning;Wu, Wen-Hsin;Lai, Cheng-Wei;Kuo, Pei-Hsin;Chiang, Po-Hung;Lin, Kai-Hsin;Wu, Tzu-Hua, 盧孟佑;林凱信   +1 more
core   +1 more source

Deferasirox Targeting Ferroptosis Synergistically Ameliorates Myocardial Ischemia Reperfusion Injury in Conjunction With Cyclosporine A

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Ferroptosis, an iron‐dependent form of regulated cell death, is a major cell death mode in myocardial ischemia reperfusion (I/R) injury, along with mitochondrial permeability transition‐driven necrosis, which is inhibited by cyclosporine A ...
Kosei Ishimaru, Masataka Ikeda, Hiroko Deguchi Miyamoto, Shun Furusawa, Ko Abe, Masatsugu Watanabe, Takuya Kanamura, Satoshi Fujita, Ryohei Nishimura, Takayuki Toyohara, Shouji Matsushima, Tomoko Koumura, Ken‐ichi Yamada, Hirotaka Imai, Hiroyuki Tsutsui, Tomomi Ide   +15 more
doaj   +1 more source

Perbedaan Kadar Thyroid Stimulating Hormone dan Free Thyroxine pada Pasien Talasemia Β-Mayor dengan Kelasi Besi Deferasirox dan Deferiprone

Sari Pediatri, 2018
Latar belakang. Talasemia β Mayor merupakan kelainan herediter yang disebabkan gangguan produksi rantai globin. Transfusi rutin menyebabkan kelebihan besi yang tertimbun dalam jaringan sehingga menyebabkan kardiomiopati, gangguan liver, dan komplikasi ...
Aries - Krisbiyantoro, Harsono Salimo, Annang Giri Moelyo   +2 more
doaj   +1 more source

Signs of deferasirox genotoxicity

, 2014
Iron overload is a major health problem for patients who have to have continuous blood transfusions. It brings some metabolic problems together. Various iron chelating agents are being used for treatment of hemochromatosis which arises from excess iron ...
Ila H.B., Topaktas M., Büyükleyla M., Arslan M.   +3 more
core   +2 more sources

Protective Effects of Vitamin C Concomitant Treatment on Deferasirox-induced Renal Toxicity in Rats

Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Arāk, 2020
Background and Aim: Deferasirox (Exjade) is an iron-chelating drug used in patients with beta-thalassemia major. Oxidative stress is among f the major causes of nephrotoxicity and its progression.
Taha Fereydouni, Saeed Hajihashemi, Parsa Yousefichaijan, Ali Rahbari   +3 more
doaj